Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival

Abstract Background The anticancer drug paclitaxel is primarily metabolized in the liver. Previous studies have indicated a correlation between impaired liver function and paclitaxel toxicity, which may indicate dose reduction. Since the evidence is limited, the aim of this study was to investigate...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Marieke Schmidt, Robin Vernooij, Merel van Nuland, Erin Smeijsters, Lot Devriese, Nadia Haj Mohammad, Thom Hermens, Julian Stammers, Christina Swart, Toine Egberts, Saskia Haitjema, Laureen Lammers
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Subjects:	Paclitaxel toxicity Impaired liver function paclitaxel dose modifications
Online Access:	https://doi.org/10.1186/s12885-024-13330-2